Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$118.7MMiss by $25.9M
EPS-$0.30Beat by $0.05
Revenue estimate$144.6M
EPS estimate-$0.35

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$183.7M
EPS estimate-$1.43

Financials

Q3 2025

Income statement

See full
Revenue$118.7M+147%
Operating income-$14.5M+42.3%
Net income-$12.6M+46.3%
EPS (diluted)-$0.30+50.8%

Balance sheet

See full
Cash & equivalents$115.3M-34.6%
Total debt$82.5M+12.1%
Total equity$335.1M+41.1%
Total assets$534.6M+42.1%

Cash flow

See full
CapEx$1.9M+577%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.51B+102%
Enterprise value$2.48B+117%
P/S6.9×-2.7×

Profitability

See full
Operating margin-23.9%-10.5pp
Net margin-22.2%-9.8pp

Returns & leverage

See full
Return on equity-28.3%-9.7pp
Debt / equity0.2×-0.1×
Current ratio4.3×-1.1×

Segments

By segment

See full
Reportable Segment$118.7M+147%

FAQ

When did Tarsus Pharmaceuticals, Inc. report Q3 2025 earnings?
Tarsus Pharmaceuticals, Inc. (TARS) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Tarsus Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
Tarsus Pharmaceuticals, Inc. reported revenue of $118.7M and eps of $-0.30 for Q3 2025.
Did Tarsus Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $144.6M by $25.9M. EPS beat the consensus estimate of $-0.35 by $0.05.
How did Tarsus Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 146.7% from $48.1M a year earlier and eps grew 50.8% from $-0.61.
Where can I find Tarsus Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001819790-25-000120) and the 10-Q periodic report (0001819790-25-000121) directly on SEC EDGAR. The filing index links above go to sec.gov.